On April 30, 2026, the FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B Bulks List - which would eliminate the remaining legal pathway for 503B outsourcing facilities to compound these medications in bulk
Patients with high cholesterol typically require specific lipid-modifying therapy, most commonly statins, as recommended by NICE guidelines (NG238)
Many of the studies available are case reports or clinical trials with small sample sizes or short durations
GLP-1 Medications and Thyroid Medication Interactions Semaglutide and tirzepatide slow gastric emptyingthe rate at which food leaves the stomach
To view or add a comment, sign in More from this author Explore related topics Explore content categories
Triggering insulin production and regulating blood sugar levels